DRIO

$7.99-0.25 (-3.03%)

Market ClosedAs of Mar 20, 8:00 PM UTC

DarioHealth Corp.

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$7.99
Potential Upside
5%
Whystock Fair Value$8.39
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryHealth Information Services

DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by dat...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$54.00M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.16
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-56.47%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
4.02

Recent News

GuruFocus.com
Mar 19, 2026

DarioHealth Corp (DRIO) Q4 2025 Earnings Call Highlights: Strategic Growth Amid Revenue Challenges

DarioHealth Corp (DRIO) reports sequential revenue growth and strong gross margins, despite a decline in annual revenue due to a legacy client non-renewal.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Moby
Mar 19, 2026

DarioHealth Corp. Q4 2025 Earnings Call Summary

Moby summary of DarioHealth Corp.'s Q4 2025 earnings call

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Motley Fool
Mar 19, 2026

DarioHealth (DRIO) Q4 2025 Earnings Transcript

Erez Raphael, Chief Executive Officer of DarioHealth Corp. He will be joined by our President and Chief Commercial Officer, Steven C. Nelson, and Chen Franco-Yehuda, our Chief Financial Officer. A copy of the release can be found on the Investor Relations page of DarioHealth Corp.’s website.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
MarketBeat
Mar 19, 2026

DarioHealth Q4 Earnings Call Highlights

DarioHealth (NASDAQ:DRIO) executives highlighted record commercial momentum and continued cost reductions on the company’s fourth-quarter and year-end 2025 earnings call, while also addressing the revenue impact of a single legacy customer non-renewal and outlining expectations for accelerating grow

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Zacks
Mar 19, 2026

DarioHealth Corp. (DRIO) Reports Q4 Loss, Beats Revenue Estimates

DarioHealth (DRIO) delivered earnings and revenue surprises of +48.88% and +2.17%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

BEARISH
Negative press. News cycle fixated on risk factors or misses.